NO792643L - Modifiserte gresspollen-antigener. - Google Patents

Modifiserte gresspollen-antigener.

Info

Publication number: NO792643L
Authority: NO; Norway
Prior art keywords: antigen; agb; grass pollen; cells; modified
Prior art date: 1978-08-15

Application number

NO792643A

Other languages

English (en)

Norwegian (no)

Inventor

Arthur Malley

Original Assignee

Research Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-08-15

Filing date

1979-08-14

Publication date

1980-02-18

1979-08-14 Application filed by Research Corp filed Critical Research Corp

1980-02-18 Publication of NO792643L publication Critical patent/NO792643L/no

Links

101000588258 Taenia solium Paramyosin Proteins 0.000 claims description 54
239000000427 antigen Substances 0.000 claims description 45
108091007433 antigens Proteins 0.000 claims description 45
102000036639 antigens Human genes 0.000 claims description 45
238000000034 method Methods 0.000 claims description 25
210000001744 T-lymphocyte Anatomy 0.000 claims description 17
230000000890 antigenic effect Effects 0.000 claims description 17
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
239000004473 Threonine Substances 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 10
229940046528 grass pollen Drugs 0.000 claims description 9
230000001590 oxidative effect Effects 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 8
210000004027 cell Anatomy 0.000 claims description 8
238000007539 photo-oxidation reaction Methods 0.000 claims description 8
206010020751 Hypersensitivity Diseases 0.000 claims description 7
101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 claims description 7
235000005875 quercetin Nutrition 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
230000008707 rearrangement Effects 0.000 claims description 6
238000003385 ring cleavage reaction Methods 0.000 claims description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
230000004048 modification Effects 0.000 claims description 4
238000012986 modification Methods 0.000 claims description 4
238000007254 oxidation reaction Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
230000001024 immunotherapeutic effect Effects 0.000 claims description 3
230000003647 oxidation Effects 0.000 claims description 3
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 2
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
125000003118 aryl group Chemical class 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
229960001285 quercetin Drugs 0.000 claims description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
108010071384 Peptide T Proteins 0.000 claims 1
239000007864 aqueous solution Substances 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
238000009738 saturating Methods 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
210000002966 serum Anatomy 0.000 description 13
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 11
210000003719 b-lymphocyte Anatomy 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 8
229940024606 amino acid Drugs 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 6
208000026935 allergic disease Diseases 0.000 description 6
230000027455 binding Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000004202 carbamide Substances 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000011835 investigation Methods 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
108010023244 Lactoperoxidase Proteins 0.000 description 3
102000045576 Lactoperoxidases Human genes 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
230000007815 allergy Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
229940057428 lactoperoxidase Drugs 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
239000013566 allergen Substances 0.000 description 2
229960004784 allergens Drugs 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000011888 foil Substances 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000003504 photosensitizing agent Substances 0.000 description 2
239000000049 pigment Substances 0.000 description 2
210000004896 polypeptide structure Anatomy 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000746983 Phleum pratense Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
125000004387 flavanoid group Chemical group 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
238000007248 oxidative elimination reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
QZRSVBDWRWTHMT-UHFFFAOYSA-M silver;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound [Ag+].OC(=O)CC(O)(C([O-])=O)CC(O)=O QZRSVBDWRWTHMT-UHFFFAOYSA-M 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
-1 threonine Chemical class 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nonmetallic Welding Materials (AREA)
Cosmetics (AREA)

NO792643A 1978-08-15 1979-08-14 Modifiserte gresspollen-antigener. NO792643L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US05/933,907 US4215036A (en)	1978-08-15	1978-08-15	Modified grass pollen antigens

Publications (1)

Publication Number	Publication Date
NO792643L true NO792643L (no)	1980-02-18

Family

ID=25464673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO792643A NO792643L (no)	1978-08-15	1979-08-14	Modifiserte gresspollen-antigener.

Country Status (15)

Country	Link
US (1)	US4215036A (fr)
JP (1)	JPS5551026A (fr)
AU (1)	AU526205B2 (fr)
BE (1)	BE878197A (fr)
CA (1)	CA1137078A (fr)
DE (1)	DE2932604A1 (fr)
DK (1)	DK337479A (fr)
ES (1)	ES483374A1 (fr)
FI (1)	FI792430A7 (fr)
FR (1)	FR2433341A1 (fr)
GB (1)	GB2031433B (fr)
NL (1)	NL7906183A (fr)
NO (1)	NO792643L (fr)
SE (1)	SE7906793L (fr)
ZA (1)	ZA794060B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0038154B1 (fr) *	1980-04-15	1983-09-21	Beecham Group Plc	Allergènes modifiés à l'aide de polysarcosines
SE8303401D0 (sv) *	1983-06-15	1983-06-15	Pharmacia Ab	Beredning och dess anvendning
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
JPS62162963A (ja) *	1986-01-10	1987-07-18	Sadao Shiosaka	金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
US4990336A (en) *	1989-02-08	1991-02-05	Biosearch, Inc.	Sustained release dosage form
US5126147A (en) *	1990-02-08	1992-06-30	Biosearch, Inc.	Sustained release dosage form
US6274552B1 (en)	1993-03-18	2001-08-14	Cytimmune Sciences, Inc.	Composition and method for delivery of biologically-active factors
ZA946765B (en) *	1993-09-02	1996-02-15	Dartmouth College	Methods of prolonged suppression of humoral immunity
US20010055581A1 (en) *	1994-03-18	2001-12-27	Lawrence Tamarkin	Composition and method for delivery of biologically-active factors
US7229841B2 (en) *	2001-04-30	2007-06-12	Cytimmune Sciences, Inc.	Colloidal metal compositions and methods
US6407218B1 (en)	1997-11-10	2002-06-18	Cytimmune Sciences, Inc.	Method and compositions for enhancing immune response and for the production of in vitro mabs
DE602004032025D1 (de) *	2003-06-23	2011-05-12	Biotech Tools Sa	Epitop-zusammensetzung zur enterischen verabreichung hergestellt durch hydrolyse von antigenen strukturen mit chymotrypsin
US20050175583A1 (en) *	2003-12-02	2005-08-11	Lawrence Tamarkin	Methods and compositions for the production of monoclonal antibodies
EP1715971A4 (fr) *	2004-01-28	2010-10-13	Cytimmune Sciences Inc	Compositions metalliques colloidales fonctionnalisees
US20110014118A1 (en) *	2007-09-21	2011-01-20	Lawrence Tamarkin	Nanotherapeutic colloidal metal compositions and methods
KR20100123674A (ko) *	2007-09-21	2010-11-24	싸이티뮨 사이언스, 인크.	나노치료제 콜로이드성 금속 조성물 및 방법
CA2706700A1 (fr)	2007-11-08	2009-05-14	Cytimmune Sciences, Inc.	Compositions et procedes de production d'anticorps

1978
- 1978-08-15 US US05/933,907 patent/US4215036A/en not_active Expired - Lifetime
1979
- 1979-08-03 FI FI792430A patent/FI792430A7/fi not_active Application Discontinuation
- 1979-08-06 ZA ZA00794060A patent/ZA794060B/xx unknown
- 1979-08-07 GB GB7927437A patent/GB2031433B/en not_active Expired
- 1979-08-07 AU AU49632/79A patent/AU526205B2/en not_active Ceased
- 1979-08-10 DE DE19792932604 patent/DE2932604A1/de not_active Withdrawn
- 1979-08-10 BE BE0/196694A patent/BE878197A/fr unknown
- 1979-08-10 FR FR7920510A patent/FR2433341A1/fr active Granted
- 1979-08-13 DK DK337479A patent/DK337479A/da not_active Application Discontinuation
- 1979-08-14 CA CA000333758A patent/CA1137078A/fr not_active Expired
- 1979-08-14 ES ES483374A patent/ES483374A1/es not_active Expired
- 1979-08-14 SE SE7906793A patent/SE7906793L/xx not_active Application Discontinuation
- 1979-08-14 NO NO792643A patent/NO792643L/no unknown
- 1979-08-14 NL NL7906183A patent/NL7906183A/nl not_active Application Discontinuation
- 1979-08-15 JP JP10395179A patent/JPS5551026A/ja active Pending

Also Published As

Publication number	Publication date
JPS5551026A (en)	1980-04-14
AU526205B2 (en)	1982-12-23
DK337479A (da)	1980-02-16
FR2433341B1 (fr)	1983-03-11
US4215036A (en)	1980-07-29
DE2932604A1 (de)	1980-02-28
ZA794060B (en)	1980-08-27
NL7906183A (nl)	1980-02-19
FI792430A7 (fi)	1981-01-01
FR2433341A1 (fr)	1980-03-14
AU4963279A (en)	1980-02-21
GB2031433A (en)	1980-04-23
SE7906793L (sv)	1980-02-16
BE878197A (fr)	1979-12-03
ES483374A1 (es)	1980-04-16
CA1137078A (fr)	1982-12-07
GB2031433B (en)	1982-10-13

Publication	Publication Date	Title
NO792643L (no)	1980-02-18	Modifiserte gresspollen-antigener.
King	1976	Chemical and biological properties of some atopic allergens
Norman	1998	Immunotherapy: past and present
Metz et al.	2003	Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines
Pati et al.	1996	Immunogenicity of outer membrane protein of Pasteurella multocida in buffalo calves
Gleich et al.	1975	Immunoglobulin E antibodies to pollen allergens account for high percentages of total immunoglobulin E protein
US5840700A (en)	1998-11-24	Methods of producing transfer factor
Gieni et al.	1993	Allergen-specific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergen
Ekramoddoullah et al.	1982	Allergenic cross-reactivity of cytochromes c of Kentucky bluegrass and perennial ryegrass pollens
Jungersen et al.	1999	Experimental Ascaris suum infection in the pig: protective memory response after three immunizations and effect of intestinal adult worm population
Su et al.	1996	Immunologic and physicochemical studies of Bermuda grass pollen antigen BG60
US4256732A (en)	1981-03-17	Modified grass pollen antigens
REISMAN et al.	1979	Clinical and immunological studies of venom immunotherapy
Perrudet-Badoux et al.	1975	Trichinella infestation in mice genetically selected for high and low antibody production
Stewart-Tull	1991	The assessment and use of adjuvants
Oka et al.	1979	Purification of two types of sea-squirt antigens
Saelinger et al.	1974	Hypersensitivity responses to bee venom and to mellitin
Kuo et al.	1977	A new allergen from the perienteric fluid of Ascaris suum with respect to charges
Tan	1983	Improvement of Malayan cobra (Naja naja sputatrix) antivenin
Malley et al.	1979	Chemical modification of timothy grass pollen antigen B—I.: Loss of antibody binding properties
Yamamoto et al.	2002	Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation
Perrudet-Badoux et al.	1974	Isolation and properties of a soluble antigen of Trichinella spiralis
Machnicka et al.	1986	Host serum proteins in Taenia saginata metacestode fluid
Leventhal et al.	1975	Cuticular reactivity of early larval stages of Ascaris suum: binding of fractions of immune serum to the surface of infective and parasitic stage larvae as detected by the mixed antiglobulin test
Erhard et al.	1991	Influence of various adjuvants on the synthesis of specific antibodies of chicken, sheep and rabbit following immunization with an hapten